FDA accepts protocol for new Traumakine trial
Faron Pharmaceuticals Oy ("Faron" or the "Company") FDA accepts protocol for new Traumakine trial in ARDS Company announcement, 09 March 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the U.S. Food and Drug Administration (FDA) has accepted the proposed protocol design for the next Traumakine study in ARDS patients, following the Company's protocol submission announced on 6 February 2020. The trial protocol